Trial Profile
Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx [pegylated liposomal doxorubicin hydrochloride] as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 25 Aug 2008 New trial record.